VLB Therapeutics to Report Year-End 2021 Financial Results on March 23

$VBLT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VBLT alert in real time by email

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open. Professor Dror Harats, M.D., Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.

Call Details:

Wednesday, March 23, 2022 at 8:30am ET
Conference ID: 13727878
US: 1-877-407-9208
Israel Local: 1-809-406-247
International: 1-201-493-6784
Webcast: https://edge.media-server.com/mmc/p/6ntrdxh8

 

About VBL Therapeutics

Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL's novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that are designed to harness the body's innate biological processes to provide unique solutions for significant unmet medical needs. VBL's lead oncology product candidate, ofranergene obadenovec (`ofra-vec`, or VB-111), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576

daniel@lifesciadvisors.com



Primary Logo

Get the next $VBLT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VBLT

DatePrice TargetRatingAnalyst
7/20/2022Outperform → Perform
Oppenheimer
7/20/2022Buy → Neutral
H.C. Wainwright
7/18/2022$5.50Outperform
Oppenheimer
4/28/2022$5.00Buy
Chardan Capital Markets
More analyst ratings

$VBLT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Notable Labs Closes Merger Transaction With VBL Therapeutics

    - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

    Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted t

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

    MODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable Labs ("Notable") at the annual and special meeting (the "Meeting") for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number of ordinary shares, nominal value of NIS 0.01 ("VBL Ordinary Shares") held, are encouraged to vote "FOR" the Merger and related proposals described in the definitive proxy statement/prospectus/information statement previously filed by VBL with the U.S. Securities and Exchange Commission (the "SEC") in connection with

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VBLT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VBLT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VBLT
SEC Filings

See more

$VBLT
Leadership Updates

Live Leadership Updates

See more
  • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

    JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

    $DRTS
    $MACA
    $VBLT
    Medical/Dental Instruments
    Health Care
    Blank Checks
    Finance
  • VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

    CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Comm

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

    TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will cont

    $NBSE
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VBLT
Financials

Live finance-specific insights

See more
  • Notable Labs Closes Merger Transaction With VBL Therapeutics

    - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

    Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

    OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VBLT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more